Comparison of the Efficacy and Tolerability of the Addition of AVANDIA to Submaximal Doses of Metformin
Status:
Completed
Trial end date:
2003-02-13
Target enrollment:
Participant gender:
Summary
This was a randomized, double-blind, double dummy, multicenter study to assess the safety,
efficacy and tolerability of the addition of RSG (rosiglitazone) to sub-maximal MET
(metformin) combination relative to maximal MET monotherapy in subjects with type 2 DM
(diabetes mellitus). The total duration of the study was approximately 20 months. The study
consisted of a two-week washout period, a four to seven-week MET titration period, and a
24-week randomized treatment phase in which subjects, stratified by prior therapy, received
either RSG + MET combination therapy or MET monotherapy.